Daily FNArena News - Small Caps

The market responded hastily and impatiently to BigAir’s weak FY13 result, rails Microequities, given acquisitions will really hit their straps in FY14.

As the population of diabetics increases alarmingly a company with a device to control the disease has the world at its feet.

Microcap specialist Microequities explains why it remains at arm’s length from software company Corum Ltd.

Biotech stock Bionomics is undervalued as its therapeutics program has been enhanced with the acquisition of Eclipse, according to Bell Potter.

Integrated Research offers opportunity for exposure to high tech arena, according to Moelis.

Despite a trial setback, Starpharma has some pundits seeing good value in multiple applications of its Dendrimer technology.

Robust demand for mining and communications technology signals strong outlook for Codan, according to Moelis.

RBS Morgans sees a favourable set-up for biotech Alchemia.

A solid full year profit result from Technology One and the expectation of further growth and potential capital management see both UBS and BA-ML retain Buy ratings on the stock.

Gold explorer Mount Magnet South has attracted DJ Carmichael’s attention as it prepares to become a producer next year.